Citation: | ZHANG Yi'nan, JI Xiaojian, HU Jiawen, WANG Yiwen, ZHANG Jianglin, HUANG Feng, ZHU Jian. Clinical characteristics of patients with ankylosing spondylitis combined enthesitis[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2022, 43(3): 264-269. DOI: 10.3969/j.issn.2095-5227.2022.03.005 |
[1] |
Taurog JD,Chhabra A,Colbert RA. Ankylosing spondylitis and axial spondyloarthritis[J]. N Engl J Med,2016,375(13): 1303. doi: 10.1056/NEJMc1511695
|
[2] |
Benjamin M,McGonagle D. Entheses: tendon and ligament attachment sites[J]. Scand J Med Sci Sports,2009,19(4): 520-527. doi: 10.1111/j.1600-0838.2009.00906.x
|
[3] |
Schett G,Lories RJ,D'Agostino MA,et al. Enthesitis: from pathophysiology to treatment[J]. Nat Rev Rheumatol,2017,13(12): 731-741. doi: 10.1038/nrrheum.2017.188
|
[4] |
Kristensen S,Christensen JH,Schmidt EB,et al. Assessment of enthesitis in patients with psoriatic arthritis using clinical examination and ultrasound[J]. Muscles Ligaments Tendons J,2016,6(2): 241-247.
|
[5] |
De Winter JJ,Paramarta JE,De Jong HM,et al. Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis[J]. RMD Open,2019,5(1): e000802. doi: 10.1136/rmdopen-2018-000802
|
[6] |
Falcao S,Castillo-Gallego C,Peiteado D,et al. Can we use enthesis ultrasound as an outcome measure of disease activity in spondyloarthritis?A study at the Achilles level[J]. Rheumatology (Oxford),2015,54(9): 1557-1562. doi: 10.1093/rheumatology/keu399
|
[7] |
Laatiris A,Amine B,Ibn Yacoub Y,et al. Enthesitis and its relationships with disease parameters in Moroccan patients with ankylosing spondylitis[J]. Rheumatol Int,2012,32(3): 723-727. doi: 10.1007/s00296-010-1658-0
|
[8] |
Benegas M,Muñoz-Gomariz E,Font P,et al. Comparison of the clinical expression of patients with ankylosing spondylitis from Europe and Latin America[J]. J Rheumatol,2012,39(12): 2315-2320. doi: 10.3899/jrheum.110687
|
[9] |
Braun J,Brandt J,Listing J,et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial[J]. Lancet,2002,359(9313): 1187-1193. doi: 10.1016/S0140-6736(02)08215-6
|
[10] |
Fournié B. Pathology and clinico-pathologic correlations in spondyloarthropathies[J]. Jo Bone Spine,2004,71(6): 525-529. doi: 10.1016/j.jbspin.2004.02.002
|
[11] |
Turan Y,Duruöz MT,Cerrahoglu L. Relationship between enthesitis, clinical parameters and quality of life in spondyloarthritis[J]. Joint Bone Spine,2009,76(6): 642-647. doi: 10.1016/j.jbspin.2009.03.005
|
[12] |
Mease PJ. Measures of psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), mander/Newcastle enthesitis index (MEI), Leeds enthesitis index (LEI), spondyloarthritis research consortium of Canada (SPARCC), maastricht ankylosing spondylitis enthesis score (MASES), Leeds dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness therapy-fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI)[J]. Arthritis Care Res (Hoboken), 2011, 63(Suppl 11): S64-S85.
|
[13] |
Mease PJ,Van den Bosch F,Sieper J,et al. Performance of 3 enthesitis indices in patients with peripheral spondyloarthritis during treatment with adalimumab[J]. J Rheumatol,2017,44(5): 599-608. doi: 10.3899/jrheum.160387
|
[14] |
Sieper J,Poddubnyy D. Axial spondyloarthritis[J]. Lancet,2017,390(10089): 73-84. doi: 10.1016/S0140-6736(16)31591-4
|
[15] |
Solmaz D,Bakirci S,Jibri Z,et al. Psoriasis is an independent risk factor for entheseal damage in axial spondyloarthritis[J]. Semin Arthritis Rheum,2020,50(1): 42-47. doi: 10.1016/j.semarthrit.2019.06.016
|
[16] |
Mease PJ,Heijde DV,Karki C,et al. Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US-based corrona registry[J]. Arthritis Care Res (Hoboken),2018,70(11): 1661-1670. doi: 10.1002/acr.23534
|
[17] |
De Winter JJ,Van Mens LJ,Van der Heijde D,et al. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis[J]. Arthritis Res Ther,2016,18(1): 196. doi: 10.1186/s13075-016-1093-z
|
[18] |
Rezvani A,Bodur H,Ataman S,et al. Correlations among enthesitis, clinical, radiographic and quality of life parameters in patients with ankylosing spondylitis[J]. Mod Rheumatol,2014,24(4): 651-656. doi: 10.3109/14397595.2013.850182
|
[19] |
Bowness P. Hla-b27[J]. Annu Rev Immunol,2015,33: 29-48. doi: 10.1146/annurev-immunol-032414-112110
|
[20] |
López-Medina C,Moltó A,Dougados M. Peripheral manifestations in spondyloarthritis and their effect: an ancillary analysis of the ASAS-COMOSPA study[J]. J Rheumatol,2020,47(2): 211-217. doi: 10.3899/jrheum.181331
|
[21] |
Mease PJ,Liu M,Rebello S,et al. Characterization of patients with axial spondyloarthritis by enthesitis presence: data from the corrona psoriatic arthritis/spondyloarthritis registry[J]. ACR Open Rheumatol,2020,2(7): 449-456. doi: 10.1002/acr2.11154
|
[22] |
Baraliakos X,Van den Berg R,Braun J,et al. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis[J]. Rheumatology (Oxford),2012,51(8): 1378-1387. doi: 10.1093/rheumatology/kes026
|
[23] |
D'Agostino MA,Olivieri I. Enthesitis[J]. Best Pract Res Clin Rheumatol,2006,20(3): 473-486. doi: 10.1016/j.berh.2006.03.007
|
[24] |
Nadon V,Moltó A,Etcheto A,et al. Clinical peripheral enthesitis in the DESIR prospective longitudinal axial spondyloarthritis cohort[J]. Clin Exp Rheumatol,2019,37(4): 561-565.
|
[25] |
Zhang HY,Liang J,Qiu JL,et al. Ultrasonographic evaluation of enthesitis in patients with ankylosing spondylitis[J]. J Biomed Res,2017,31(2): 162-169.
|